Credit: Shutterstock photoBioTime, Inc.BTX was a big mover last session, as the company saw its shares rise above 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the company as the stock is now trading above the volatile price range of $2.88 to $3.13 since Jan 30.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
BioTime currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
BioTime, Inc. Price
BioTime, Inc. Price | BioTime, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industryisGalapagos NV GLPG , which sports a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here.
Is BTX going up? Or down? Predict to see what others think: Up or Down
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >> >
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioTime, Inc. (BTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
